Erratum to "Male breast cancer: An update in diagnosis, treatment and molecular profiling" [Maturitas 65 (2010) 308-314] (DOI:10.1016/j.maturitas.2010.01.012);Male breast cancer: An update in diagnosis, treatment and molecular profiling

Maturitas

Volumn 65, Issue 4, 2010, Pages 308-314

  Onami, Susan ^a   Ozaki, Melanie ^a   Mortimer, Joanne E ^b   Pal, Sumanta Kumar ^a  

^a Division of Genitourinary Malignancies   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

BRCA; Estrogen receptor; HER2; Male breast cancer; Olaparib; PARP inhibitors; Progesterone receptor; Trastuzumab; Trastuzumab DM1

Indexed keywords

ANGIOGENESIS INHIBITOR; AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GONADORELIN DERIVATIVE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; TAMOXIFEN;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL FEATURE; HISTOPATHOLOGY; HUMAN; MALE; REVIEW;

EID: 77649185718     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2010.04.003     Document Type: Erratum

References (89)

1. Ravdin P.M., Cronin K.A., Howlader N., et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 356 (2007) 1670-1674
2. Writing Group for the Women's Health Initiative Investigators: Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial. JAMA 2002 288:321-33.
3. Stang A., and Thomssen C. Decline in breast cancer incidence in the United States: what about male breast cancer?. Breast Cancer Res Treatment 112 (2008) 595-596
4. Speirs V., and Shaaban A. The rising incidence of male breast cancer. Breast Cancer Res Treatment 115 (2009) 429-430
5. Giordano S.H., Buzdar A.U., and Hortobagyi G.N. Breast cancer in men. Ann Inter Med 137 (2002) 678-687
6. Ewertz M., Holmberg L., Karjalainen S., et al. Incidence of male breast cancer in Scandinavia, 1943-1982. Int J Cancer 43 (1989) 27-31
7. Fentiman I.S., Fourquet A., and Hortobagyi G.N. Male breast cancer. Lancet 367 (2006) 595-604
8. Thalib L., and Hall P. Survival of male breast cancer patients: population-based cohort study. Cancer Sci 100 (2009) 292-295
9. Mitra D., Manna A., Sikdar S.K., et al. Clinicopathological study and its prognostic implication in male breast carcinoma. J Indian Med Assoc 105 (2007) 681-683 686
10. Jamal S., Mamoon N., Mushtaq S., et al. Carcinoma of the male breast: a study of 141 cases from northern Pakistan. Asian Pac J Cancer Prev 7 (2006) 119-121
11. O'Malley C., Shema S., White E., et al. Incidence of male breast cancer in California, 1988-2000: racial/ethnic variation in 1759 men. Breast Cancer Res Treatment 93 (2005) 145-150
12. Anderson WF, Jatoi I, Tse J, et al. Male Breast Cancer: A Population-Based Comparison With Female Breast Cancer. J Clin Oncol:JCO.2009.23.8162, 2009.
13. Brinton L.A., Richesson D.A., Gierach G.L., et al. Prospective evaluation of risk factors for male breast cancer. J Natl Cancer Inst 100 (2008) 1477-1481
14. Brinton L, Carreon J, Gierach G, et al. Etiologic factors for male breast cancer in the U.S. Veterans Affairs medical care system database. Breast Cancer Research and Treatment 119:185-92.
15. Hultborn R., Hanson C., Köpf I., et al. Prevalence of Klinefelter's syndrome in male breast cancer patients. Anticancer Res 17 (1997) 4293-4297
16. Sasco A.J., Lowenfels A.B., and Pasker-de Jong P. Review article: epidemiology of male breast cancer. A meta-analysis of published case-control studies and discussion of selected aetiological factors. Int J Cancer 53 (1993) 538-549
17. Lee U.J., and Jones J.S. Incidence of prostate cancer in male breast cancer patients: a risk factor for prostate cancer screening. Prostate Cancer Prostatic Dis 12 (2008) 52-56
18. Terris M.K., and McCallum S.W. Aromatase inhibitors for male infertility. J Urol 168 (2002) 1509
19. Grenader T., Goldberg A., and Shavit L. Second cancers in patients with male breast cancer: a literature review. J Cancer Survivorship 2 (2008) 73-78
20. Lowe T., Luu T., Shen J., et al. Male breast cancer 15 years after allogeneic hematopoietic cell transplantation including total body irradiation for recurrent acute lymphoblastic leukemia. Onkologie 31 (2008) 266-269
21. Unek I.T., Alacacioglu A., Tarhan O., et al. Synchronous appearance of male breast cancer and pancreatic cancer 15 years after the diagnosis of testicular cancer-report of a case. J BUON 13 (2008) 421-424
22. Rao G, Giordano SH, Liu J, et al. The Association of Breast Cancer and Meningioma in Men and Women. Neurosurgery 65:483-9 10.1227/01.NEU.0000350876.91495.E0, 2009.
23. Morrogh M., and King T.A. The significance of nipple discharge of the male breast. Breast J 15 (2009) 632-638
24. dos Santos V.M., Cintra Osterne E.M., de Castro R.A., et al. Bilateral male breast cancer: too many concerns?. Asian Pac J Cancer Prev 8 (2007) 640-641
25. Flynn L.W., Park J., Patil S.M., et al. Sentinel lymph node biopsy is successful and accurate in male breast carcinoma. J Am College Surgeons 206 (2008) 616-621
26. Gu G.L., Wang S.L., Wei X.M., et al. Axillary metastasis as the first manifestation of male breast cancer: a case report. Cases J 1 (2008) 285
27. Joshi A., Kapila K., and Verma K. Fine needle aspiration cytology in the management of male breast masses. Nineteen years of experience. Acta Cytol 43 (1999) 334-338
28. Rosen D.G., Laucirica R., and Verstovsek G. Fine needle aspiration of male breast lesions. Acta Cytol 53 (2009) 369-374
29. Stalsberg H., Thomas D.B., Rosenblatt K.A., et al. Histologic types and hormone receptors in breast cancer in men: a population-based study in 282 United States men. Cancer Causes Contr 4 (1993) 143-151
30. Bhatia A., Uma Nahar Saikia, and Kumar Y. Rare coexistence of invasive papillary carcinoma with infiltrating ductal carcinoma in male breast: report of a case. Int J Surg Pathol 16 (2008) 311-313
31. Farkas A., Istok R., Szekely E., et al. Pigmented papillary carcinoma: a rare tumor of the male breast. Pathol Oncol Res 14 (2008) 341-343
32. Brahmi S.A., El M'rabet F.Z., Akesbi Y., et al. Intracystic papillary carcinoma associated with ductal carcinoma in situ in a male breast: a case report. Cases J 2 (2009) 7260
33. Dragoumis D.M., and Tsiftsoglou A.P. Intracystic papillary carcinoma associated with ductal carcinoma in situ in a male breast. J Postgrad Med 54 (2008) 39-40
34. Hussain A, Sweeney K, Salman R, et al. Intracystic papillary carcinoma of the male breast: a case report and review of the literature. Irish J Med Sci.
35. Olu-Eddo A.N., and Ohanaka C.E. Intracystic papillary carcinoma of the breast in a Nigerian male: case report. Niger Postgrad Med J 15 (2008) 270-271
36. Romics Jr. L., O'Brien M.E., Relihan N., et al. Intracystic papillary carcinoma in a male as a rare presentation of breast cancer: a case report and literature review. J Med Case Reports 3 (2009) 13
37. Yoshida M, Mouri Y, Yamamoto S, et al. Intracystic invasive papillary carcinoma of the male breast with analyses of loss of heterozygosity on chromosome 16q. Breast Cancer.
38. Giordano S.H., Cohen D.S., Buzdar A.U., et al. Breast carcinoma in men. Cancer 101 (2004) 51-57
39. Nahleh Z.A., Srikantiah R., Safa M., et al. Male breast cancer in the veterans affairs population. Cancer 109 (2007) 1471-1477
40. Avisar E., McParland E., Dicostanzo D., et al. Prognostic factors in node-negative male breast cancer. Clin Breast Cancer 7 (2006) 331-335
41. Shah P., Robbani I., and Shah O. Clinicopathological study of male breast carcinoma: 24 years of experience. Ann Saudi Med 29 (2009) 288-293
42. Slamon D.J., Clark G.M., Wong S.G., et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 (1987) 177-182
43. Slamon D.J., Godolphin W., Jones L.A., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244 (1989) 707-712
44. Slamon D, Leyland-Jones B, Shak S: Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER21/MBC) markedly increases anticancer activity: A randomized multinational controlled phase III trial. ProcAm Soc Clin Oncol 17:(abstr 377), 1998.
45. Geyer C.E., Forster J., Lindquist D., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355 (2006) 2733-2743
46. Beeram M, Krop I, Modi S, et al. A phase I study of trastuzumab-MCC-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (BC). Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 1042.
47. Clemens M, Kaufman B, Mackey JR, et al. Trastuzumab plus anastrozole may prolong overall survival in postmenopausal women with HER2-positive, hormone-dependent metastatic breast cancer: Results of a post-hoc analysis from the TAnDEM study. ASCO Breast Cancer Symposium 2007 (abstr 231).
48. Chu Q, Goldstein L, Murray N, et al. A phase I, open-label study of the safety, tolerability and pharmacokinetics of lapatinib (GW572016) in combination with letrozole in cancer patients. Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. Vol 23, No. 16S, Part I of II (June 1 Supplement), 2005: 3001.
49. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. 2004 116:281-97.
50. Fassan M., Baffa R., Palazzo J., et al. MicroRNA expression profiling of male breast cancer. Breast Cancer Res 11 (2009) R58
51. Burstein H.J., Elias A.D., Rugo H.S., et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 26 (2008) 1810-1816
52. Miller K., Wang M., Gralow J., et al. Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer. N Engl J Med 357 (2007) 2666-2676
53. Bianchi G., Loibl S., Zamagni C., et al. Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer. Anti-Cancer Drugs 20 (2009) 616-624 10.1097/CAD.0b013e32832b2ea0
54. Miles D., Chan A., Romieu G., et al. Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. J Clin Oncol (Meeting Abstracts) 26 (2008) LBA1011-
55. Robert N.J., Dieras V., Glaspy J., et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). J Clin Oncol (Meeting Abstracts) 27 (2009) 1005
56. Clevenger C.V., Furth P.A., Hankinson S.E., et al. The role of prolactin in mammary carcinoma. Endocr Rev 24 (2003) 1-27
57. Tworoger S.S., Sluss P., and Hankinson S.E. Association between plasma prolactin concentrations and risk of breast cancer among predominately premenopausal women. Cancer Res 66 (2006) 2476-2482
58. Ferreira M., Mesquita M., Quaresma M., et al. Prolactin receptor expression in gynaecomastia and male breast carcinoma. Histopathology 53 (2008) 56-61
59. Howell S., Anderson E., Hunter T., et al. Prolactin receptor antagonism reduces the clonogenic capacity of breast cancer cells and potentiates doxorubicin and paclitaxel cytotoxicity. Breast Cancer Res 10 (2008) R68
60. Tallal Y., Kelly Dakin H., Daniel R., et al. Survivin and COX-2 expression in male breast carcinoma (2009), Churchill Livingstone, Breast (Edinburgh, Scotland) p. 228-32
61. Foster F., Owens T., Tanianis-Hughes J., et al. Targeting inhibitor of apoptosis proteins in combination with ErbB antagonists in breast cancer. Breast Cancer Res 11 (2009) R41
62. Krysan K., Reckamp K.L., Sharma S., et al. The potential and rationale for COX-2 inhibitors in lung cancer. Anticancer Agents Med Chem 6 (2006) 209-220
63. Gomez-Pozo A., Sanchez-Navarro I., Nistal M., et al. MALDI profiling of human lung cancer subtypes. PLoS ONE 4 (2009) e7731
64. Rudlowski C., Schulten H.-J., Golas M.M., et al. Comparative genomic hybridization analysis on male breast cancer. Int J Cancer 118 (2006) 2455-2460
65. Evans D., Bulman M., Young K., et al. BRCA1/2 mutation analysis in male breast cancer families from North West England. Familial Cancer 7 (2008) 113-117
66. Basham V., Lipscombe J., Ward J., et al. BRCA1 and BRCA2 mutations in a population-based study of male breast cancer. Breast Cancer Res 4 (2002) R2
67. Pal S.K., and Mortimer J. Triple-negative breast cancer: novel therapies and new directions. Maturitas 63 (2009) 269-274
68. Tutt A., Robson M., Garber J.E., et al. Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. J Clin Oncol (Meeting Abstracts) 27 (2009) CRA501-
69. Byrski T., Foszczynska-Kloda M., Huzarski T., et al. Cisplatin chemotherapy in the treatment of BRCA1-positive metastatic breast cancer (MBC). J Clin Oncol (Meeting Abstracts) 27 (2009) 1099
70. Ribeiro G., and Swindell R. Adjuvant tamoxifen for male breast cancer (MBC). Br J Cancer 65 (1992) 252-254
71. Bagley C.S., Wesley M.N., Young R.C., et al. Adjuvant chemotherapy in males with cancer of the breast. Am J Clin Oncol 10 (1987) 55-60
72. Farrow J.H., and Adair F.E. Effect of orchidectomy on skeletal metastases from cancer of the male breast. Science 95 (1942) 654
73. Jaiyesimi I.A., Buzdar A.U., Sahin A.A., et al. Carcinoma of the male breast. Ann Intern Med 117 (1992) 771-777
74. Gibson L, Lawrence D, Dawson C, et al. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane Database Syst Rev:CD003370, 2009.
75. Doyen J, Italiano A, Largillier R, et al. Aromatase inhibition in male breast cancer patients: biological and clinical implications. Ann Oncol:mdp450, 2009.
76. Giordano S.H., and Hortobagyi G.N. Leuprolide acetate plus aromatase inhibition for male breast cancer. J Clin Oncol 24 (2006) e42-43
77. Soon Wong N., Seong Ooi W., and Pritchard K.I. Role of gonadotropin-releasing hormone analog in the management of male metastatic breast cancer is uncertain. J Clin Oncol 25 (2007) 3787
78. Robertson J.F.R., Llombart-Cussac A., Rolski J., et al. Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST Study. J Clin Oncol 27 (2009) 4530-4535
79. Howell A., Robertson J.F.R., Quaresma Albano J., et al. Fulvestrant, Formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 20 (2002) 3396-3403
80. de la Haba Rodriguez J.R., Porras Quintela I., Pulido Cortijo G., et al. Fulvestrant in advanced male breast cancer. Ann Oncol 20 (2009) 1896-1897
81. Montero A.J., Talebi T.N., Zhu Y., et al. Successful use of biweekly gemcitabine plus nab-paclitaxel in two male patients with stage iv breast cancer: case reports and review of the literature. Am J Ther (2009)
82. Carmona-Bayonas A. Potential benefit of maintenance trastuzumab and anastrozole therapy in male advanced breast cancer. Breast (Edinburgh, Scotland) 16 (2007) 323-325
83. Jim W., James K., Claire M., et al. Are males with early breast cancer treated differently from females with early breast cancer in Australia and New Zealand?. Breast (Edinburgh, Scotland) 18 (2009) 378-381
84. Gough D.B., Donohue J.H., Evans M.M., et al. A 50-year experience of male breast cancer: is outcome changing?. Surg Oncol 2 (1993) 325-333
85. Fisher B., Anderson S., Bryant J., et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347 (2002) 1233-1241
86. Veronesi U., Cascinelli N., Mariani L., et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 347 (2002) 1227-1232
87. Golshan M., Rusby J., Dominguez F., et al. Breast conservation for male breast carcinoma. Breast (Edinburgh, Scotland) 16 (2007) 653-656
88. National Comprehensive Cancer Network Guidelines: Breast Cancer (Available on-line at http://www.nccn.org; last accessed January 8, 2009).
89. Yoney A., Kucuk A., and Unsal M. Male breast cancer: a retrospective analysis. Cancer/Radiothérapie 13 (2009) 103-107